Pricing

Boston Immune Technologies & Therapeutics

0 followers

‌

BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.

Industries

Biotechnology, Therapeutics

Headquarters

Winchester, United States

Employees

1-10

Links

Org chart

Russell LaMontagne

CEO

Russell LaMontagne

Collapse

David Brooks

Chief Medical Officer

VP of Manufacturing

Finance Director

Director of Legal

Director of Preclinical Development

Mohammad Razvi

Director of Clinical Operations & Development

Teams

This company has no teams yet

Similar companies

Thermo Fisher Scientific

155 followers

Biogen

114 followers

Alexion Pharmaceuticals

34 followers

Cytiva

10 followers

Merck

211 followers

Pendulum

4 followers

Alector

3 followers

BridgeBio

2 followers

Tessera Therapeutics

2 followers

Nurix

2 followers

Vial

5 followers

Explore companies